No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects

Yu Kyong Kim,1,* Jun Gi Hwang,1,* Min Kyu Park1,2 1Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheongju, Republic of Korea; 2Department of Pharmacology and Clinical Pharmacology, Dong-A University College of Medicine, Dong-A Un...

Full description

Bibliographic Details
Main Authors: Kim YK, Hwang JG, Park MK
Format: Article
Language:English
Published: Dove Medical Press 2021-04-01
Series:Drug Design, Development and Therapy
Subjects:
clinical trial
antidiabetic drug
pharmacokinetic interaction
thiazolidinedione
type 2 diabetes
Online Access:https://www.dovepress.com/no-relevant-pharmacokinetic-drugndashdrug-interaction-between-the-sodi-peer-reviewed-fulltext-article-DDDT

Internet

https://www.dovepress.com/no-relevant-pharmacokinetic-drugndashdrug-interaction-between-the-sodi-peer-reviewed-fulltext-article-DDDT

Similar Items